SCHEMBL23687458

SCHEMBL23687458

CC(C)(C)OC(=O)c1ccc(OC[C@@]2(C=O)CCC(F)(F)c3cc(Cl)ccc32)c([N+](=O)[O-])c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.36
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ POLB P06746 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 6/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ HPGD P15428 3/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ S1PR4 O95977 1/20 0.34
▸ MAPT P10636 3/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ TP53 P04637 1/20 0.34
▸ MEN1 O00255 2/20 0.33
▸ HTT P42858 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29552814 1.00 LMNA (0.36) LMNASMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL23670407 0.88 KDM4E (0.39) LMNASMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL19285489 0.87 LMNA (0.38) LMNASMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL29553154 0.87 LMNA (0.38) LMNASMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL23670505 0.87 LMNA (0.38) LMNASMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL19285488 0.87 LMNA (0.38) LMNASMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL29553941 0.87 LMNA (0.38) LMNASMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL17558480 0.85 KDM4E (0.38) LMNASMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL17558482 0.85 KDM4E (0.38) LMNASMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL29436357 0.85 KDM4E (0.38) LMNASMN1; SMN2POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230052348-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2023-02-16 — — US disclosed
US-20210230189-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2021-07-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230189-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN MCL1, BCL9, BCL2L1 LMNA 1191/4885SMN1; SMN2 1807/4885POLB 2772/4885
US-20230052348-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN MCL1, BCL9, BCL2L1 LMNA 1191/4885SMN1; SMN2 1807/4885POLB 2772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback